



# STATE OF CONNECTICUT

## DEPARTMENT OF PUBLIC HEALTH IMMUNIZATION PROGRAM

**PLEASE COPY THIS FOR ALL HEALTH CARE PROVIDERS  
IN YOUR PRACTICE**

**TO:** All Users of State Supplied Vaccine

**FROM:** Vincent Sacco, MS *VAS*      Lynn Sosa, MD *Lynn Sosa*  
Immunization Program Manager    Deputy State Epidemiologist

**DATE:** February 1, 2011

**SUBJECT:** **New Recommendations for Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) and Meningococcal Conjugate (MCV4) vaccines**

The primary purpose of this communication is to notify you of new recommendations for the use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) and Meningococcal Conjugate (MCV4) vaccines.

### **Tdap Vaccine**

On October 27, 2010, the Advisory Committee on Immunization Practices (ACIP) approved the following additional recommendations: 1) use of Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine, 2) use of Tdap in certain adults aged 65 years and older, and 3) use of Tdap in children aged 7 through 10 years who are not fully vaccinated against pertussis. Fully vaccinated is defined as 5 doses of DTaP or 4 doses of DTaP if the fourth dose was administered on or after the fourth birthday.

A summary of these changes is listed below. The full ACIP recommendation can be accessed at:  
[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s\\_cid=mm6001a4\\_e&source=govdelivery](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6001a4.htm?s_cid=mm6001a4_e&source=govdelivery).

**Beginning March 1, 2011 providers can begin to use state supplied Tdap according to these new recommendations.**

### **MCV4 Vaccine**

Two new recommendations were approved by ACIP: 1) routine vaccination of adolescents, preferably at age 11 or 12 years, with a booster dose at age 16 years and 2) a 2-dose primary series administered 2 months apart for persons aged 2 through 54 years with persistent complement component deficiency (e.g., C5--C9, properidin, factor H, or factor D) and functional or anatomic asplenia, and for adolescents with human immunodeficiency virus (HIV) infection. A summary of these changes is listed below. The full ACIP recommendation can be viewed at:

[http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm?s\\_cid=mm6003a3\\_e&source=govdelivery](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6003a3.htm?s_cid=mm6003a3_e&source=govdelivery).

**Beginning March 1, 2011 providers can begin to use state supplied MCV4 to vaccinate any 16–18 year old patient in need of a booster dose of vaccine.**

Attached is an updated VFC Vaccine Eligibility criteria form as of March 1, 2011. As always, if you have any questions, please contact the Immunization Program at (860) 509-7929.

***Summary of updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine ACIP 2010***

**General Recommendations**

For routine use, adolescents aged 11 through 18 years who have completed the recommended childhood DTP/DTaP vaccination series should receive a single dose of Tdap. Adolescents should preferably receive Tdap at the 11 to 12 year-old preventive health-care visit.

**Timing of Tdap (New)**

- Can be administered regardless of interval since the last tetanus and diphtheria-toxoid containing vaccine.

**Children Aged 7 Through 10 Years (New)**

- Those not fully vaccinated against pertussis\* and for whom no contraindication to pertussis vaccine exists should receive a single dose of Tdap.
- Those never vaccinated against tetanus, diphtheria, or pertussis or who have unknown vaccination status should receive a series of three vaccinations containing tetanus and diphtheria toxoids. The first of these three doses should be Tdap.

**\* Fully vaccinated is defined as 5 doses of DTaP or 4 doses of DTaP if the fourth dose was administered on or after the fourth birthday.**

***Summary of meningococcal conjugate vaccine recommendations (MCV4) ACIP 2010***

<b>Risk Group*</b>	<b>Primary series</b>	<b>Booster Dose</b>
Persons 11–18 years of age	1 dose, preferably at 11-12 years	At age 16 if primary dose given at 11 or 12 years
		At age 16–18 years if primary dose given at age 13–15 years
		No booster needed if primary dose given on or after age 16

\* For additional risk groups, see the full ACIP recommendations for MCV4.

**Vaccine for Children's Program (VFC)**  
**Eligibility Criteria for State of CT provided vaccines March 2011**

Vaccine	Age Group	VFC Status of Children		CPT Code(s)
		VFC-Eligible <sup>1</sup>	Non-VFC Children	
Varicella Dose 1 Dose 2	12 months-18 years <sup>2</sup> 15 months-18 years	YES YES	YES YES	90716 90716
Hepatitis B	Newborns in hospital Children 0-18 years	YES YES	YES YES	90744 90744
Td	Children 7-18 years <sup>3</sup>	YES	YES	90714
MMR (Doses 1 & 2)	12 months-18 years College entry	YES YES	YES YES	90707 90707
Pneumococcal Conjugate Vaccine (PCV 13)	6 weeks-71 months	YES	<b>NO</b>	90670
Influenza	6 months-18 years	YES	<b>NO</b>	90655 90656 90657 90658 90660
DTaP	2 months – 6 years	YES	YES	90700
Hib	2-59 months	YES	YES	90648
IPV	2 months-18 years	YES	YES	90713
Meningococcal Conjugate (MCV4) Dose 1 Dose 2	11-18 years 16-18 years	YES YES	YES YES	90734 90734
Tdap	7-18 years <sup>4</sup>	YES	YES	90715
Hepatitis A	12 months-18 years	YES	<b>NO</b>	90633
Rotavirus	6 weeks-8 months	YES	<b>NO</b>	90681
DTaP/IPV	4-6 years	YES	YES	90696
HPV (males & females)	9-18 years	YES	<b>NO</b>	90649
DTaP/IPV/Hib	2-59 months	YES	YES	90698

1 VFC eligibility is defined as follows: (a) Medicaid enrolled; (b) NO health insurance; or (c) American Indian or Alaskan native. In addition those individuals who are underinsured (have health insurance that does not fully cover immunizations) can be referred to a Federally Qualified Health Center (FQHC) to be immunized with VFC-supplied vaccine. Non-VFC Children refers to patients who have private insurance that fully covers the cost of immunizations.

2 Susceptible children who do not have a clinical history of chicken pox.

3 Td vaccine can be given to children 7-18 years of age to complete their primary series, or to those children 7-18 years of age who are in need of a Tetanus containing vaccine and cannot receive Tdap.

4 Tdap vaccine should be administered routinely to children at the 11-12 year old preventive health care visit, and to children 7-10 years old who have not been fully vaccinated against pertussis and for whom no contraindication to pertussis containing vaccine exists.

Revised 1/21/11